标题
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
作者
关键词
Hematologic malignancies, Immune checkpoints, CAR-T, Immunotherapy, CTLA-4, PD-1, New targets
出版物
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-06-11
DOI
10.1186/s13045-019-0746-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
- (2019) Stephen M. Ansell et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
- (2019) Anas Younes et al. Lancet Haematology
- NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
- (2019) Arlene O. Siefker-Radtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
- (2018) Frank Vari et al. BLOOD
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
- (2018) Miriam Y. Kim et al. CELL
- FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
- (2018) Emily Y. Jen et al. CLINICAL CANCER RESEARCH
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR-T cells: the long and winding road to solid tumors
- (2018) Maria Michela D’Aloia et al. Cell Death & Disease
- CART19 in Hodgkin lymphoma: are we driving the right model?
- (2018) Catherine S. Diefenbach BLOOD
- A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma
- (2018) Tycel Phillips et al. INVESTIGATIONAL NEW DRUGS
- A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.
- (2018) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
- (2018) Tapan M. Kadia et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML
- (2018) Samuel John et al. MOLECULAR THERAPY
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
- (2018) Sebastian Kobold et al. Frontiers in Oncology
- Hyperviscosity syndrome in splenic marginal zone lymphoma
- (2018) Raeye Daniel et al. BLOOD
- The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
- (2018) Patrick Williams et al. CANCER
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells
- (2018) Sergey N. Zolov et al. CYTOTHERAPY
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
- (2017) Mika Shapiro et al. HAEMATOLOGICA
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Cytokines in Cancer Immunotherapy
- (2017) Thomas A. Waldmann Cold Spring Harbor Perspectives in Biology
- Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
- (2017) Mika Shapiro et al. HAEMATOLOGICA
- The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
- (2017) Isabel Gonçalves Silva et al. EBioMedicine
- Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL
- (2016) N. Daver et al. BLOOD
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
- (2016) Xiaojuan Liu et al. CELL RESEARCH
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation
- (2016) David Michonneau et al. IMMUNITY
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- (2016) Marco Ruella et al. JOURNAL OF CLINICAL INVESTIGATION
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia
- (2016) Carsten Riether et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
- (2015) M. Al-Hussaini et al. BLOOD
- Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study
- (2015) Y. Yang et al. BLOOD
- Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- (2015) J. Kiyasu et al. BLOOD
- First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
- (2015) Taofeek Kunle Owonikoko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors
- (2015) Xunlei Kang et al. CELL CYCLE
- A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression
- (2015) Yoshikane Kikushige et al. Cell Stem Cell
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- The immune receptor Tim-3 mediates activation of PI3 kinase/mTOR and HIF-1 pathways in human myeloid leukaemia cells
- (2015) Alexandr Prokhorov et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
- (2015) Frauke M. Schnorfeil et al. Journal of Hematology & Oncology
- PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
- (2015) B Paiva et al. LEUKEMIA
- Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
- (2015) A Ray et al. LEUKEMIA
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
- (2015) Quan-shun Wang et al. MOLECULAR THERAPY
- The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development
- (2015) Xunlei Kang et al. NATURE CELL BIOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tyrosine kinase inhibitor–induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling
- (2015) Carsten Riether et al. Science Translational Medicine
- PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation
- (2015) Y Kong et al. Blood Cancer Journal
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
- (2015) José I. Quetglas et al. Cancer Immunology Research
- A motif in LILRB2 critical for Angptl2 binding and activation
- (2014) M. Deng et al. BLOOD
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells
- (2014) Walter Moises Tobias Braga et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
- (2014) M. Janakiram et al. CLINICAL CANCER RESEARCH
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
- (2014) Nizar M. Tannir et al. INVESTIGATIONAL NEW DRUGS
- Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
- (2014) I Pizzitola et al. LEUKEMIA
- TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin’s lymphoma
- (2014) Z-Z Yang et al. LEUKEMIA
- The bone marrow niche for haematopoietic stem cells
- (2014) Sean J. Morrison et al. NATURE
- T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
- (2013) A. Mardiros et al. BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
- (2013) J. H. Myklebust et al. BLOOD
- The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
- (2013) D. Brusa et al. HAEMATOLOGICA
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Lenalidomide enhances anti-myeloma cellular immunity
- (2012) Katarina Luptakova et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression
- (2012) Christian Schürch et al. JOURNAL OF CLINICAL INVESTIGATION
- T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
- (2012) M Aigner et al. LEUKEMIA
- Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development
- (2012) Junke Zheng et al. NATURE
- Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
- (2011) D. J. Andorsky et al. CLINICAL CANCER RESEARCH
- Loss of B7-H1 Expression by Recipient Parenchymal Cells Leads to Expansion of Infiltrating Donor CD8+ T Cells and Persistence of Graft-Versus-Host Disease
- (2011) X. Li et al. JOURNAL OF IMMUNOLOGY
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
- (2011) Sara Raponi et al. LEUKEMIA & LYMPHOMA
- Stem cell gene expression programs influence clinical outcome in human leukemia
- (2011) Kolja Eppert et al. NATURE MEDICINE
- A human memory T cell subset with stem cell–like properties
- (2011) Luca Gattinoni et al. NATURE MEDICINE
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma
- (2010) Keichiro Mihara et al. BRITISH JOURNAL OF HAEMATOLOGY
- In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors
- (2010) Céline Berthon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
- (2010) Yoshikane Kikushige et al. Cell Stem Cell
- Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
- (2010) P. Yu et al. CLINICAL CANCER RESEARCH
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts
- (2009) R. Le Dieu et al. BLOOD
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
- (2009) L. Zhang et al. BLOOD
- B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
- (2009) Ryo Yamamoto et al. CANCER SCIENCE
- Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
- (2009) Liqing Jin et al. Cell Stem Cell
- Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival
- (2009) Simone Muenst et al. HUMAN PATHOLOGY
- High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma
- (2009) Joaquim Carreras et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
- (2008) R. Yamamoto et al. BLOOD
- Hematopoiesis: An Evolving Paradigm for Stem Cell Biology
- (2008) Stuart H. Orkin et al. CELL
- CD70 as a therapeutic target in human malignancies
- (2008) Iqbal S Grewal EXPERT OPINION ON THERAPEUTIC TARGETS
- Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia
- (2008) Luc Xerri et al. HUMAN PATHOLOGY
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search